tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Scheel AK et al. Severe neurotoxicity of tacrolimus (FK506) after renal transplantation: two case reports. 2001 Nov-Dec Transplant. Proc. pmid:11750573
McCauley J et al. The effects of FK 506 on renal function after liver transplantation. 1990 Transplant. Proc. pmid:1689887
Kang Y et al. Acute hemodynamic effects of FK 506 during and after orthotopic liver transplantation. 1990 Transplant. Proc. pmid:1689889
Morris-Stiff G et al. Prospective randomized study comparing FK 506 (Prograft) and cyclosporine A (Neoral) as primary immunosuppression in cadaveric renal transplants at a single institution: interim report of the first 80 cases. 1998 Transplant. Proc. pmid:9636525
Woodle ES et al. Meta-analysis of FK 506 and mycophenolate mofetil refractory rejection trials in renal transplantation. Refractory Rejection Meta-Analysis Study Group. 1998 Transplant. Proc. pmid:9636526
Youhua Z et al. Clinical study of FK 506 in renal transplant recipients. 2000 Transplant. Proc. pmid:11119900
Büsing M et al. Mycophenolate mofetil/tacrolimus/single-shot versus azathioprine/cyclosporine/ATG in pancreas-kidney transplantation: results of a prospective randomized single-center study. 1998 Transplant. Proc. pmid:9532155
Shitrit D et al. Tacrolimus-induced hemolytic uremic syndrome case presentation in a lung transplant recipient. 2003 Transplant. Proc. pmid:12644073
González E et al. Everolimus represents an advance in immunosuppression for patients who have developed cancer after renal transplantation. 2009 Jul-Aug Transplant. Proc. pmid:19715911
Crespo-Leiro MG et al. Replacement of cyclosporine by tacrolimus for immunosuppression in heart transplant patients: safety and efficacy. 2002 Transplant. Proc. pmid:11959213
Rajnoch J et al. Regulators of angiogenesis in renal ischemia/reperfusion injury in normotensive and hypertensive rats: effect of tacrolimus. 2005 Jan-Feb Transplant. Proc. pmid:15808641
Gregory CR et al. Effects of treatment with cyclosporine, FK 506, rapamycin, mycophenolic acid, or deoxyspergualin on vascular muscle proliferation in vitro and in vivo. 1993 Transplant. Proc. pmid:7679842
McMichael J et al. Evaluation of a novel "intelligent" dosing system for optimizing FK 506 therapy. 1991 Transplant. Proc. pmid:1721275
Valdivia LA et al. Prolonged survival of hearts obtained from chimeric donors in a mouse to rat xenotransplant model. 1996 Transplant. Proc. pmid:8623371
Chan KL et al. Porcine small bowel transplantation with FK506 as a single immunosuppressant. 2001 Transplant. Proc. pmid:11406260
Platz KP et al. Indications for mycophenolate mofetil therapy in hepatitis C-patients undergoing liver transplantation. 1998 Transplant. Proc. pmid:9636596
Moriuchi H et al. Mechanisms of immunosuppressive effects of FK 506 in light of apoptosis of hepatocytes and infiltrating lymphocytes in rat allografted livers. 2000 Transplant. Proc. pmid:11120182
Oliveira DB and Chang R Report of the first 118 tacrolimus-treated patients at St George's Hospital, London. 1999 Transplant. Proc. pmid:10576047
Jurewicz WA Immunological and nonimmunological risk factors with tacrolimus and Neoral in renal transplant recipients: an interim report. 1999 Transplant. Proc. pmid:10576048
Tian JH et al. Induction with and without antithymocyte globulin combined with cyclosporine/tacrolimus-based immunosuppression in renal transplantation: a meta-analysis of randomized controlled trials. 2009 Transplant. Proc. pmid:19917365
Tarasewicz A et al. Rapamycin as a therapy of choice after renal transplantation in a patient with tuberous sclerosis complex. 2009 Transplant. Proc. pmid:19917366
San Segundo D et al. Study of B-cell subpopulations in lung transplant recipients with posttransplant infection. 2012 Transplant. Proc. pmid:23146491
Egawa H et al. Lymphoproliferative disorders in patients undergoing living-related liver transplantation. 1998 Transplant. Proc. pmid:9474982
Le Dinh H et al. Evolution of native kidney function after pancreas transplantation alone. 2012 Transplant. Proc. pmid:23146535
Tanabe K et al. Excellent outcome of ABO-incompatible living kidney transplantation under pretransplantation immunosuppression with tacrolimus, mycophenolate mofetil, and steroid. 2004 Transplant. Proc. pmid:15518791
Jain AB et al. One thousand consecutive primary orthotopic liver transplants under FK 506: survival and adverse events. 1995 Transplant. Proc. pmid:7533353
Rosborough SL et al. Identification of FKBP-related proteins with antibodies of predetermined specificity and isolation by FK 506 affinity chromatography. 1991 Transplant. Proc. pmid:1721306
Zeevi A et al. In vitro assessment of FK 506 immunosuppressive activity in transplant patients. 1991 Transplant. Proc. pmid:1721307
Foroncewicz B et al. Anti-CD25 and tacrolimus therapy may not prevent early primary biliary cirrhosis recurrence after liver transplantation: two case reports. 2003 Transplant. Proc. pmid:14529924
Kim SW et al. Decreased formation of nitric oxide in rats treated with FK506. 2003 Transplant. Proc. pmid:12591357
Nakamura Y et al. Evaluation of appropriate blood level in continuous intravenous infusion from trough concentrations after oral administration based on area under trough level in tacrolimus and cyclosporine therapy. 2005 Transplant. Proc. pmid:15919445
Furukawa H and Todo S Evolution of immunosuppression in liver transplantation: contribution of cyclosporine. 2004 Transplant. Proc. pmid:15041353
Takaori K et al. Basic study on immunologic effects of cyclosporine and FK 506 for application to pancreatic transplantation. 1992 Transplant. Proc. pmid:1376531
Ohtsuka S et al. The effect of short-term FK 506 therapy on pancreas transplantation using the cuff technique in rats. 1992 Transplant. Proc. pmid:1376532
Ko S et al. Significance of newly developed liposomal FK 506 in canine liver transplantation. 1995 Transplant. Proc. pmid:7533406
Shaw BW et al. FK 506 for rescue treatment of acute and chronic rejection in liver allograft recipients. 1991 Transplant. Proc. pmid:1721338
Junge G et al. Microchimerism in patients after orthotopic liver transplantation: a prognostic indicator? 2002 Transplant. Proc. pmid:12176475
Böttiger Y et al. Effect of bile flow on the absorption of tacrolimus in liver allograft transplantation. 2002 Transplant. Proc. pmid:12176476
Orlandi V et al. Tacrolimus-associated myositis: a case report in a renal transplant patient. 2004 Transplant. Proc. pmid:15110639
Kilian K et al. FK-506 (tacrolimus) therapy for an unusual SLE-like disease. 1998 Transplant. Proc. pmid:9865322
Fontana I et al. Severe rhabdomyolysis and acute renal failure in a kidney transplant patient treated with tacrolimus and chimaeric CD25 monoclonal antibody. 2004 Transplant. Proc. pmid:15110640
Schorlemmer HU and Kurrle R Combination therapy of malononitrilamides and tacrolimus (FK 506) induced long-term xenograft survival. 1998 Transplant. Proc. pmid:9865337
Larriba J et al. Pharmacogenetics of immunosuppressant polymorphism of CYP3A5 in renal transplant recipients. 2010 Jan-Feb Transplant. Proc. pmid:20172323
Fischereder M et al. Gynaecomastia following solid organ transplantation. 2002 Transplant. Proc. pmid:12270376
Dahmen U et al. Onset of liver regeneration after subtotal resection is inhibited by the use of new immunosuppressive drugs. 2002 Transplant. Proc. pmid:12270412
Gelens MA et al. Do blood pressure and arterial wall properties change after conversion from cyclosporine to tacrolimus? 2005 Transplant. Proc. pmid:15919498
Perego C et al. Orthotopic liver-small bowel transplantation in pigs: study of immunologic parameters during therapy with FK 506-based immunosuppressive regimens. 1996 Transplant. Proc. pmid:8907908
Alessiani M et al. Combined FK 506 and mycophenolate mofetil immunosuppression prolongs survival after small bowel transplantation in pigs. 1996 Transplant. Proc. pmid:8907922
Takahara S et al. Excellent results following 3 years of tacrolimus immunosuppression in kidney transplantation recipients in Japan: overall analysis of more than 1000 patients. 2002 Transplant. Proc. pmid:12176500
Hayakawa K et al. Involvement of clonal deletion in immunotolerance induction: tests of Tacrolimus administration in rat renal transplantation. 1994 Transplant. Proc. pmid:7520608
Yoshimura R et al. Study of the effect of immunosuppressive agents on renal cytochrome P-450 system in the rat. 1994 Transplant. Proc. pmid:7520610
Lorho R et al. Improved liver function and decreased hepatitis C viral load after tacrolimus was replaced by cyclosporine. 2005 Jul-Aug Transplant. Proc. pmid:16182838
Feitoza CQ et al. A role for HO-1 in renal function impairment in animals subjected to ischemic and reperfusion injury and treated with immunosuppressive drugs. 2007 Transplant. Proc. pmid:17362747
Wijnen RM et al. Toxicity of FK 506 in the cynomolgus monkey: noncorrelation with FK 506 serum levels. 1991 Transplant. Proc. pmid:1721371
Venkataramanan R et al. Pharmacokinetics of FK 506 following oral administration: a comparison of FK 506 and cyclosporine. 1991 Transplant. Proc. pmid:1703355
Karakulska-Prystupiuk E et al. Pericarditis in Patients With Chronic Graft-vs-Host Disease. 2018 Transplant. Proc. pmid:30177139
Nishimura Y et al. A trial to obtain donor-specific immunotolerance using a vascularized thymus allograft. 1998 Transplant. Proc. pmid:9838684
Damotte D et al. Morphologic features of large bowel biopsies in combined small and large bowel transplantations could predict clinical rejection. 1999 Feb-Mar Transplant. Proc. pmid:10083252
Ota H et al. Intrathymic microchimerism predicts rejection response in allograft recipients. 1997 Feb-Mar Transplant. Proc. pmid:9123279
Paul LC Overview of side effects of immunosuppressive therapy. 2001 Transplant. Proc. pmid:11377462
Kiuchi T et al. Experience of tacrolimus-based immunosuppression in living-related liver transplantation complicated with graft tuberculosis: interaction with rifampicin and side effects. 1996 Transplant. Proc. pmid:8962229
Rodrigo E et al. Histopathological findings according to Banff-97 classification system comparing tacrolimus versus cyclosporine. 2002 Transplant. Proc. pmid:12176550
Hatakeyama S et al. A switch from conventional twice-daily tacrolimus to once-daily extended-release tacrolimus in stable kidney transplant recipients. 2012 Transplant. Proc. pmid:22310594
Nakamura Y et al. Safety and efficacy of conversion from twice-daily tacrolimus (prograf) to once-daily prolonged-release tacrolimus (graceptor) in stable kidney transplant recipients. 2012 Transplant. Proc. pmid:22310595
Jiang Y et al. Dyslipidemia in human kidney transplant recipients receiving cyclosporine and tacrolimus is associated with different expression of CD36 on peripheral blood monocytes. 2011 Transplant. Proc. pmid:21693242
Arita S et al. Effect of FK 506 in experimental pancreas transplantation. 1995 Transplant. Proc. pmid:7536980
Mori T et al. Tacrolimus and methotrexate for the prophylaxis of graft-versus-host disease after unrelated donor cord blood transplantation for adult patients with hematologic malignancies. 2007 Transplant. Proc. pmid:17580201
Viebahn R et al. Hypoxic and reoxygenation injury in human and rat hepatocytes--influence of FK 506 and cyclosporine. 1991 Transplant. Proc. pmid:1721401
Sato K et al. Effectiveness of triple drug immunosuppression for pancreaticoduodenal allotransplantation in dogs. 1992 Transplant. Proc. pmid:1379753
Masaki Y et al. Microchimerism and rat small bowel transplantation combined with donor-type bone marrow cells. 1996 Transplant. Proc. pmid:8769154
Lauro A et al. Rejection episodes and 3-year graft survival under sirolimus and tacrolimus treatment after adult intestinal transplantation. 2007 Transplant. Proc. pmid:17580204
Morrisett JD et al. Effect of FK 506 and cyclosporine on plasma cholesterol levels in rabbits. 1991 Transplant. Proc. pmid:1721402
Murphy MP and Morris RE Brequinar sodium effectively and potently suppresses allograft rejection in a heterotopic mouse heart transplant model. 1993 Transplant. Proc. pmid:7685955
Kobayashi C et al. Suppression of corneal graft rejection in rabbits by a new immunosuppressive agent, FK-506. 1989 Transplant. Proc. pmid:2468254
Kuroki H et al. Experimental studies of vascularized allogeneic limb transplantation in the rat using a new immunosuppressive agent, FK-506: morphological and immunological analysis. 1989 Transplant. Proc. pmid:2468255
Erickson LM et al. Gene expression profiles of rat heart allografts with immunosuppression. 2001 Feb-Mar Transplant. Proc. pmid:11266960
Meloni F et al. Monocyte chemoattractant protein-1 levels in bronchoalveolar lavage fluid of lung-transplanted patients treated with tacrolimus as rescue treatment for refractory acute rejection. 2003 Transplant. Proc. pmid:12826211
Morrissey PE et al. Factors contributing to acute rejection in renal transplantation: the role of noncompliance. 2005 Transplant. Proc. pmid:15964334
Peeters P et al. Economic evaluation of Neoral versus Sandimmune maintenance therapy for de novo liver transplant patients: results from an International Randomized Controlled Trial. Milton Study Group. 1998 Transplant. Proc. pmid:9723301
Soran A et al. Renal retransplantation in elderly recipients under tacrolimus-based immunosuppression. 2000 Transplant. Proc. pmid:10812157
Formica RN et al. Sirolimus-based immunosuppression with reduce dose cyclosporine or tacrolimus after renal transplantation. 2003 Transplant. Proc. pmid:12742475
Jiménez-Pérez M et al. Everolimus plus mycophenolate mofetil as initial immunosuppression in liver transplantation. Transplant. Proc. pmid:25645779
Hasegawa A et al. Optimal use of tacrolimus in living donor renal transplantation in children. 2002 Transplant. Proc. pmid:12176635
Joo DJ et al. Comparison of the affinity column-mediated immunoassay and microparticle enzyme immunoassay methods as a tacrolimus concentration assay in the early period after liver transplantation. 2010 Transplant. Proc. pmid:21168645
Shaffer D et al. Calcineurin inhibitor avoidance versus steroid avoidance following kidney transplantation: Postoperative complications. 2006 Transplant. Proc. pmid:17175304
Kobayashi N et al. Effect of FK 506 on abdominal organ cluster transplantation in pigs. 1991 Transplant. Proc. pmid:1721434
Collier DS et al. Kidney transplantation in the dog receiving FK-506. 1987 Transplant. Proc. pmid:2445077
Neff GW et al. Sirolimus therapy in orthotopic liver transplant recipients with calcineurin inhibitor related chronic renal insufficiency. 2003 Transplant. Proc. pmid:14697970
Moreno M et al. Clinical management of tacrolimus drug interactions in renal transplant patients. 1999 Transplant. Proc. pmid:10500564
Ott R et al. Does conversion of immunosuppressive monotherapy from cyclosporine A to tacrolimus improve bone mineral density in long-term stable liver transplant recipients? 2003 Transplant. Proc. pmid:14697971
Ivulich S et al. Clinical Challenges of Tacrolimus for Maintenance Immunosuppression Post-Lung Transplantation. 2017 Transplant. Proc. pmid:29149976
García Meseguer C et al. The effect of different immunosuppression on the outcome of pediatric renal transplants. 1999 Transplant. Proc. pmid:10500577
Tur MD et al. Apolipoprotein CIII is upregulated by anticalcineurins and rapamycin: implications in transplantation-induced dyslipidemia. 2000 Transplant. Proc. pmid:11134804
Morena M et al. Low-density lipoprotein composition and oxidation are not influenced by calcineurin inhibitors in renal transplant patients. 2000 Transplant. Proc. pmid:11134805
Dalgic A et al. Liver transplantation and tacrolimus monotherapy for hepatocellular carcinoma with expanded criteria. 2005 Transplant. Proc. pmid:16213334
Jensik SC Tacrolimus (FK 506) in kidney transplantation: three-year survival results of the US multicenter, randomized, comparative trial. FK 506 Kidney Transplant Study Group. 1998 Transplant. Proc. pmid:9636494
Tamura S et al. Conversion to cyclosporine provides valuable rescue therapy for living donor adult liver transplant patients intolerant to tacrolimus: A single-center experience at the University of Tokyo. 2004 Transplant. Proc. pmid:15686738
Szabó L et al. Effect of tacrolimus on the excitatory synaptic transmission between the parallel fibers and pyramidal cells in the rat dorsal cochlear nucleus. 2010 Jul-Aug Transplant. Proc. pmid:20692476
Groth CG Immunosuppressive regimens of tomorrow. 1995 Transplant. Proc. pmid:8539797
Jiang H et al. Effect of FK 506 on heart allograft survival in highly sensitized recipient rats in comparison with cyclosporine. 1991 Transplant. Proc. pmid:1703702